Do analysts rate CLRB or GELS?

Cellectar Biosciences presently has a consensus target price of $11.00, suggesting a potential upside of 367.09%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CLRB or GELS?

Gelteq has higher revenue and earnings than Cellectar Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Gelteq $110K 107.59 -$4.30M N/A N/A

Is CLRB or GELS more profitable?

Gelteq's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Gelteq N/A N/A N/A

Do analysts recommend MDCX or GELS?

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 2,586.57%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Medicus Pharma is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, MDCX or GELS?

Gelteq has higher revenue and earnings than Medicus Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicus Pharma N/A N/A -$35.46M -$2.68 N/A Gelteq $110K 107.59 -$4.30M N/A N/A

Is MDCX or GELS more profitable?

Gelteq's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Medicus Pharma N/A -3,137.84% -311.33% Gelteq N/A N/A N/A

Does the media prefer MDCX or GELS?

In the previous week, Gelteq had 11 more articles in the media than Medicus Pharma. MarketBeat recorded 18 mentions for Gelteq and 7 mentions for Medicus Pharma. Medicus Pharma's average media sentiment score of 0.30 beat Gelteq's score of 0.30 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gelteq 1 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GELS or HOWL?

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 879.11%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has higher valuation and earnings, GELS or HOWL?

Gelteq has higher earnings, but lower revenue than Werewolf Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 107.59 -$4.30M N/A N/A Werewolf Therapeutics $1.88M 9.90 -$60.82M -$1.24 N/A

Is GELS or HOWL more profitable?

Gelteq's return on equity of 0.00% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Werewolf Therapeutics N/A -208.23% -75.12%

Does the media favor GELS or HOWL?

In the previous week, Gelteq had 7 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 18 mentions for Gelteq and 11 mentions for Werewolf Therapeutics. Gelteq's average media sentiment score of 0.30 beat Werewolf Therapeutics' score of -0.15 indicating that Gelteq is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 1 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Werewolf Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GELS or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, GELS or MYNZ?

Gelteq has higher earnings, but lower revenue than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 107.59 -$4.30M N/A N/A Mainz Biomed $659.94K 23.75 -$21.65M -$65.60 N/A

Is GELS or MYNZ more profitable?

Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Mainz Biomed N/A N/A N/A

Do analysts rate GELS or PASG?

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 140.69%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Passage Bio 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11

Which has higher earnings and valuation, GELS or PASG?

Gelteq has higher revenue and earnings than Passage Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 107.59 -$4.30M N/A N/A Passage Bio N/A N/A -$45.52M -$11.84 N/A

Is GELS or PASG more profitable?

Gelteq's return on equity of 0.00% beat Passage Bio's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Passage Bio N/A -150.88% -59.78%

Does the media refer more to GELS or PASG?

In the previous week, Gelteq had 15 more articles in the media than Passage Bio. MarketBeat recorded 18 mentions for Gelteq and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.62 beat Gelteq's score of 0.30 indicating that Passage Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gelteq 1 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gelteq (GELS) Competitors

$1.10 +0.12 (+11.62%)

As of 03:03 PM Eastern

Compare

GELS vs. CLRB, MDCX, HOWL, MYNZ, and PASG

Should you buy Gelteq stock or one of its competitors? MarketBeat compares Gelteq with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gelteq include Cellectar Biosciences (CLRB), Medicus Pharma (MDCX), Werewolf Therapeutics (HOWL), Mainz Biomed (MYNZ), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

How does Gelteq compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Cellectar Biosciences presently has a consensus target price of $11.00, suggesting a potential upside of 367.09%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Gelteq	N/A	N/A	N/A

16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gelteq has higher revenue and earnings than Cellectar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Gelteq	$110K	107.59	-$4.30M	N/A	N/A

In the previous week, Gelteq had 16 more articles in the media than Cellectar Biosciences. MarketBeat recorded 18 mentions for Gelteq and 2 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 1.43 beat Gelteq's score of 0.30 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
Gelteq	Neutral

Cellectar Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market.

Summary

Cellectar Biosciences beats Gelteq on 7 of the 12 factors compared between the two stocks.

How does Gelteq compare to Medicus Pharma?

Medicus Pharma (NASDAQ:MDCX) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Gelteq's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicus Pharma	N/A	-3,137.84%	-311.33%
Gelteq	N/A	N/A	N/A

Medicus Pharma presently has a consensus target price of $9.00, suggesting a potential upside of 2,586.57%. Given Medicus Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Medicus Pharma is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq had 11 more articles in the media than Medicus Pharma. MarketBeat recorded 18 mentions for Gelteq and 7 mentions for Medicus Pharma. Medicus Pharma's average media sentiment score of 0.30 beat Gelteq's score of 0.30 indicating that Medicus Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medicus Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gelteq	1 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medicus Pharma has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.19, meaning that its stock price is 119% less volatile than the broader market.

Gelteq has higher revenue and earnings than Medicus Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A
Gelteq	$110K	107.59	-$4.30M	N/A	N/A

Summary

Medicus Pharma and Gelteq tied by winning 5 of the 10 factors compared between the two stocks.

How does Gelteq compare to Werewolf Therapeutics?

Gelteq (NASDAQ:GELS) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 879.11%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Gelteq has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Gelteq's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Werewolf Therapeutics	N/A	-208.23%	-75.12%

In the previous week, Gelteq had 7 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 18 mentions for Gelteq and 11 mentions for Werewolf Therapeutics. Gelteq's average media sentiment score of 0.30 beat Werewolf Therapeutics' score of -0.15 indicating that Gelteq is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	1 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Werewolf Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gelteq has higher earnings, but lower revenue than Werewolf Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	107.59	-$4.30M	N/A	N/A
Werewolf Therapeutics	$1.88M	9.90	-$60.82M	-$1.24	N/A

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Werewolf Therapeutics beats Gelteq on 7 of the 13 factors compared between the two stocks.

How does Gelteq compare to Mainz Biomed?

Gelteq (NASDAQ:GELS) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Gelteq had 18 more articles in the media than Mainz Biomed. MarketBeat recorded 18 mentions for Gelteq and 0 mentions for Mainz Biomed. Gelteq's average media sentiment score of 0.30 beat Mainz Biomed's score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Neutral
Mainz Biomed	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Gelteq has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Mainz Biomed	N/A	N/A	N/A

Gelteq has higher earnings, but lower revenue than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	107.59	-$4.30M	N/A	N/A
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A

Summary

Gelteq beats Mainz Biomed on 4 of the 7 factors compared between the two stocks.

How does Gelteq compare to Passage Bio?

Gelteq (NASDAQ:GELS) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Gelteq's return on equity of 0.00% beat Passage Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Passage Bio	N/A	-150.88%	-59.78%

Passage Bio has a consensus target price of $13.25, indicating a potential upside of 140.69%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts plainly believe Passage Bio is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Passage Bio	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Gelteq had 15 more articles in the media than Passage Bio. MarketBeat recorded 18 mentions for Gelteq and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.62 beat Gelteq's score of 0.30 indicating that Passage Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gelteq	1 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Passage Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.5% of Passage Bio shares are owned by institutional investors. 4.9% of Passage Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Gelteq has a beta of -0.19, indicating that its stock price is 119% less volatile than the broader market. Comparatively, Passage Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Gelteq has higher revenue and earnings than Passage Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	107.59	-$4.30M	N/A	N/A
Passage Bio	N/A	N/A	-$45.52M	-$11.84	N/A

Summary

Passage Bio beats Gelteq on 7 of the 12 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.84M	$3.38B	$6.48B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.03	23.95	24.60
Price / Sales	107.59	320.04	536.37	171.61
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.02	8.01	10.44	6.77
Net Income	-$4.30M	$23.89M	$3.56B	$337.32M
7 Day Performance	127.84%	2.12%	0.83%	2.06%
1 Month Performance	153.56%	0.09%	1.78%	3.93%
1 Year Performance	-47.38%	44.59%	25.59%	32.29%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	0.9166 of 5 stars	$1.11 +11.6%	N/A	-52.9%	$11.84M	$110K	N/A	N/A	Short Interest Decrease Gap Up High Trading Volume
CLRB Cellectar Biosciences	4.4095 of 5 stars	$2.59 -5.8%	$11.00 +324.7%	-82.0%	$21.98M	N/A	N/A	10	Positive News Gap Up
MDCX Medicus Pharma	2.4719 of 5 stars	$0.35 -6.3%	$9.00 +2,471.4%	-87.0%	$21.17M	N/A	N/A	N/A	News Coverage Gap Down
HOWL Werewolf Therapeutics	3.2779 of 5 stars	$0.39 -8.8%	$3.75 +855.9%	-68.8%	$20.90M	$1.88M	N/A	40	Gap Up
MYNZ Mainz Biomed	N/A	$2.20 -5.6%	N/A	-5.5%	$19.93M	$659.94K	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. CLRB, MDCX, HOWL, MYNZ, and PASG

How does Gelteq compare to Cellectar Biosciences?

Summary

How does Gelteq compare to Medicus Pharma?

Summary

How does Gelteq compare to Werewolf Therapeutics?

Summary

How does Gelteq compare to Mainz Biomed?

Summary

How does Gelteq compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. CLRB, MDCX, HOWL, MYNZ, and PASG

How does Gelteq compare to Cellectar Biosciences?

Do analysts rate CLRB or GELS?

Is CLRB or GELS more profitable?

Do insiders & institutionals hold more shares of CLRB or GELS?

Which has stronger valuation & earnings, CLRB or GELS?

Does the media prefer CLRB or GELS?

Which has more volatility & risk, CLRB or GELS?

Summary

How does Gelteq compare to Medicus Pharma?

Is MDCX or GELS more profitable?

Do analysts recommend MDCX or GELS?

Does the media prefer MDCX or GELS?

Which has more risk & volatility, MDCX or GELS?

Which has higher valuation & earnings, MDCX or GELS?

Summary

How does Gelteq compare to Werewolf Therapeutics?

Do analysts prefer GELS or HOWL?

Which has more risk & volatility, GELS or HOWL?

Is GELS or HOWL more profitable?

Does the media favor GELS or HOWL?

Which has higher valuation and earnings, GELS or HOWL?

Do institutionals and insiders believe in GELS or HOWL?

Summary

How does Gelteq compare to Mainz Biomed?

Does the media refer more to GELS or MYNZ?

Do analysts recommend GELS or MYNZ?

Which has more volatility & risk, GELS or MYNZ?

Is GELS or MYNZ more profitable?

Which has preferable valuation and earnings, GELS or MYNZ?

Summary

How does Gelteq compare to Passage Bio?

Is GELS or PASG more profitable?

Do analysts rate GELS or PASG?

Does the media refer more to GELS or PASG?

Do institutionals & insiders believe in GELS or PASG?

Which has more risk & volatility, GELS or PASG?

Which has higher earnings and valuation, GELS or PASG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools